Red Blood Cell Archives

Anemia in astronauts could be a challenge for space missions

Anemia, R&D, Red Blood Cell, Space travel

The next “giant leap” for humans may be a trip to Mars, but having enough oxygen-carrying red blood cells for the journey might present a challenge, new research suggests.

January 14, 2022/by Reuters Health

Takeda and Carmine Enter $900 Million Non-Viral Gene Therapy Collaboration

Adeno-Associated Virus (AAV), Cells, Collaborations, Deals, Gene Therapy, Non-Viral Gene Therapies, Rare Diseases, Red Blood Cell, Research, RNA

Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.

June 30, 2020/by BioSpace

Solid Biosciences shares plummet as gene therapy trial halted again

Analysts, Bleeding, Clinical Hold, Duchenne Muscular Dystophy (DMD), Gene Therapy, Men, Muscle Wasting Disorders, Platelet Count, R&D, Red Blood Cell

Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

November 12, 2019/by Reuters Health

FDA Approves Rare Blood Disease Treatment Reblozyl

Anemia, Approvals, Beta Thalassemia, Erythroid maturation agents, Fast Track Designation, FDA, FDA/Regulatory, Genetic Defects, Hemoglobin, Orphan Drug Designation, Red Blood Cell, Red blood cell (RBC) transfusions, Transfusions

The U.S. FDA approved Celgene and Acceleron Pharma’s Reblozyl for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

November 11, 2019/by BioSpace

Celgene and Acceleron File BLA for Potential Blockbuster Blood Disease Treatment

Biologics License Application (BLA), Blood Diseases, Erythroid maturation agents, European Medicines Agency, FDA/Regulatory, Myelodysplastic Syndromes, Red Blood Cell

Celgene and developmental partner Acceleron Pharma are eying a potential U.S. FDA approval of a blood-disease treatment.

April 8, 2019/by BioSpace

Novartis’ crizanlizumab receives FDA Breakthrough Therapy designation for prevention of vaso-occlusive crises in sickle cell disease

Blood Cells, Blood Disorders, Blood Vessels, Breakthrough Therapy Designation, FDA, FDA/Regulatory, Red Blood Cell, Sickle Cell Disease

Novartis announced that the U.S. Food and Drug Administration granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises in patients of all genotypes with sickle cell disease.

January 8, 2019/by PR Newswire